Cefoxitin

The dosage of Cefoxitin is determined by the severity of the infection, the susceptibility of the causative organism, and the patient's overall health. According to standard clinical guidelines:

• General Infections: For mild to moderate infections, the typical dose is 1 gram every 6 to 8 hours (3 to 4 grams per day).
• Severe Infections: For life-threatening or highly resistant infections, the dose may be increased to 2 grams every 4 hours or 3 grams every 6 hours (up to 12 grams per day).
• Surgical Prophylaxis: To prevent infection during surgery, a 2-gram dose is usually given intravenously 30 to 60 minutes before the initial incision. For prolonged procedures, additional doses may be given during surgery. Prophylactic use is generally discontinued within 24 hours after surgery.
• Uncomplicated Gonorrhea: A single 2-gram IM dose is sometimes used, often accompanied by 1 gram of oral probenecid to delay excretion and prolong the drug's effect.

Cefoxitin is approved for use in pediatric patients, including neonates. However, the dosage must be carefully calculated based on the child's body weight:

• Infants and Children (3 months and older): The usual dose is 80 to 160 mg per kilogram (mg/kg) of body weight per day, divided into 4 to 6 equal doses. The total daily dose should not exceed 12 grams.
• Neonates (under 3 months): The recommended dose is 60 to 100 mg/kg/day, divided into 3 or 4 equal doses. Safety and efficacy in infants under 3 months have not been as extensively studied as in older children, so healthcare providers exercise caution in this age group.

Renal Impairment

Since Cefoxitin is primarily excreted by the kidneys, patients with reduced kidney function (renal insufficiency) require dose adjustments to prevent drug accumulation and toxicity. Adjustments are based on the Creatinine Clearance (CrCl) rate:

• CrCl 30-50 mL/min: 1-2 grams every 8-12 hours.
• CrCl 10-29 mL/min: 1-2 grams every 12-24 hours.
• CrCl 5-9 mL/min: 0.5-1 gram every 12-24 hours.
• CrCl <5 mL/min: 0.5-1 gram every 24-48 hours.
• Hemodialysis: A supplemental dose may be required after each dialysis session because the procedure removes Cefoxitin from the blood.

Hepatic Impairment

No specific dosage adjustment is typically required for patients with liver disease, as Cefoxitin is not significantly metabolized by the liver.

Elderly Patients

Older adults are more likely to have decreased renal function. Healthcare providers usually monitor kidney function closely and adjust the dose accordingly. The "start low and go slow" approach is often favored in the geriatric population.

Cefoxitin is administered by healthcare professionals in a clinical setting (hospital or infusion center).

• Intravenous (IV): The drug is injected into a large vein. It can be given as a slow injection over 3 to 5 minutes or as an intermittent infusion over 30 to 60 minutes.
• Intramuscular (IM): The drug is injected deep into a large muscle mass (such as the gluteus maximus). This route may be painful, and the powder is often reconstituted with 0.5% or 1% lidocaine (a local anesthetic) to reduce discomfort.
• Storage: Unopened vials should be stored at room temperature (20°C to 25°C). Once reconstituted, the solution's stability varies depending on the diluent used, often remaining stable for 24 hours at room temperature or 48-96 hours if refrigerated.

In a hospital setting, it is unlikely that a dose will be missed. However, if you are receiving Cefoxitin at home through an outpatient infusion service and miss a dose, contact your healthcare provider or home health nurse immediately. Do not double the next dose to catch up.

Symptoms of Cefoxitin overdose may include neuromuscular hyperexcitability or seizures, especially in patients with impaired kidney function who receive high doses. If an overdose is suspected, emergency medical treatment is required. Treatment is supportive, and Cefoxitin can be removed from the bloodstream through hemodialysis.

> Important: Follow your healthcare provider's dosing instructions exactly. Completing the full course of antibiotics is essential to ensure the infection is fully cleared and to prevent the development of antibiotic resistance.

Cefoxitin is generally well-tolerated, but like all antibiotics, it can cause side effects. The most common reactions occur at the site of administration:

• Local Reactions: Pain, tenderness, and hardness (induration) at the site of an intramuscular injection are very common.
• Thrombophlebitis: When given intravenously, Cefoxitin can cause inflammation of the vein (thrombophlebitis), which may feel like a warm, painful, or red streak along the vein.
• Gastrointestinal Issues: Diarrhea is the most common systemic side effect. It is usually mild and resolves after the medication is stopped.

These side effects may affect a smaller percentage of patients:

• Nausea and Vomiting: Some patients may feel sick to their stomach shortly after administration.
• Rash: A mild, itchy skin rash (urticaria) or redness may develop.
• Eosinophilia: An increase in a specific type of white blood cell (eosinophils) may be detected in blood tests, often indicating a mild allergic response.
• Elevated Liver Enzymes: Temporary increases in AST, ALT, and alkaline phosphatase may occur, though clinical liver damage is rare.

• Hypotension: A sudden drop in blood pressure.
• Hematologic Changes: Rare cases of leukopenia (low white blood cells), thrombocytopenia (low platelets), or hemolytic anemia (destruction of red blood cells) have been reported.
• Renal Dysfunction: Increases in serum creatinine or blood urea nitrogen (BUN), particularly in patients with pre-existing kidney issues or those taking other nephrotoxic drugs.

> Warning: Stop taking Cefoxitin and call your doctor immediately if you experience any of the following serious symptoms:

1. 1Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include swelling of the face, lips, or tongue; difficulty breathing or swallowing; wheezing; and a rapid, weak pulse.
2. 2Clostridioides difficile-Associated Diarrhea (CDAD): This is a severe form of colitis (inflammation of the colon) caused by an overgrowth of C. diff bacteria. Symptoms include watery or bloody diarrhea (occurring up to two months after the last dose), severe abdominal cramps, and fever.
3. 3Severe Skin Reactions: Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) are rare but critical conditions characterized by widespread skin peeling, blistering, and sores in the mouth or eyes.
4. 4Seizures: High doses of cephalosporins, especially in patients with kidney failure, can trigger central nervous system irritation leading to convulsions.
5. 5Unusual Bleeding or Bruising: This could indicate a rare effect on blood clotting or platelet levels.

Cefoxitin is typically used for short-term acute infections or surgical prophylaxis. However, prolonged use (longer than 10-14 days) can lead to:

• Superinfection: An overgrowth of non-susceptible organisms, such as Candida (yeast), which can cause oral thrush or vaginal yeast infections.
• Vitamin K Deficiency: Like many broad-spectrum antibiotics, Cefoxitin can interfere with the gut bacteria that produce Vitamin K, potentially leading to a prolonged prothrombin time (slower blood clotting), especially in malnourished patients.

There are currently no FDA Black Box Warnings for Cefoxitin. However, it does carry significant warnings regarding hypersensitivity and C. diff infections which are standard for the cephalosporin class.

Report any unusual symptoms or persistent side effects to your healthcare provider. While many side effects are mild, some require immediate medical intervention to prevent long-term complications.

Before starting Cefoxitin, it is critical to inform your healthcare provider of your complete medical history, particularly any history of allergies to antibiotics. Cefoxitin should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria to prevent the development of drug-resistant bacteria.

No FDA black box warnings for Cefoxitin. While Cefoxitin is a potent medication, it does not currently meet the FDA criteria for a boxed warning, which is reserved for drugs with a high risk of serious or life-threatening adverse effects.

• Allergic Reactions / Anaphylaxis Risk: There is a significant risk of cross-sensitivity between cephalosporins and penicillins. Approximately 10% of patients with a history of penicillin allergy may also be allergic to Cefoxitin. If you have ever had a severe allergic reaction (anaphylaxis) to any beta-lactam antibiotic, Cefoxitin should be avoided or used with extreme caution under close medical supervision.
• Clostridioides difficile-Associated Diarrhea (CDAD): Nearly all antibacterial agents, including Cefoxitin, can cause CDAD. This condition ranges in severity from mild diarrhea to fatal colitis. Treatment with antibiotics alters the normal flora of the colon, leading to the overgrowth of C. difficile. If diarrhea occurs during or after treatment, it must be evaluated by a physician. Anti-peristaltic drugs (like loperamide) should be avoided if CDAD is suspected.
• Nephrotoxicity: While Cefoxitin itself is not inherently toxic to the kidneys at standard doses, it can increase the risk of kidney damage when used alongside other nephrotoxic drugs, such as aminoglycosides. Monitoring of renal function is essential, especially in the elderly or those with pre-existing kidney disease.
• Superinfection: Prolonged use of Cefoxitin may result in the overgrowth of non-susceptible organisms, including fungi or resistant bacteria like Pseudomonas. If a superinfection occurs, appropriate therapy must be initiated.

Patients receiving long-term therapy or high doses of Cefoxitin may require regular laboratory monitoring:

• Renal Function Tests: Serum creatinine and BUN levels to ensure the kidneys are clearing the drug effectively.
• Complete Blood Count (CBC): To monitor for rare hematologic side effects like leukopenia or eosinophilia.
• Liver Function Tests: To check for transient elevations in liver enzymes.
• Prothrombin Time: In patients at risk for Vitamin K deficiency (e.g., those with poor nutrition or chronic liver disease).

Cefoxitin is not known to interfere with the ability to drive or operate machinery. However, if you experience side effects like dizziness or seizures (rare), you should avoid these activities until you know how the medication affects you.

While Cefoxitin does not typically cause a disulfiram-like reaction (nausea, vomiting, flushing) with alcohol—unlike some other cephalosporins like cefotetan—it is generally advisable to avoid alcohol while fighting a serious infection to allow your immune system to function optimally.

Stopping Cefoxitin too early can allow the remaining bacteria to multiply, leading to a return of the infection and contributing to antibiotic resistance. Always complete the full course as prescribed by your doctor, even if you feel better after the first few doses.

> Important: Discuss all your medical conditions, including asthma, kidney disease, or stomach problems, with your healthcare provider before starting Cefoxitin.

There are no absolute drug-drug contraindications where Cefoxitin must never be used; however, certain combinations are avoided due to extreme risk:

• Live Bacterial Vaccines (e.g., Typhoid Vaccine): Antibiotics like Cefoxitin can kill the live bacteria in the vaccine, rendering it ineffective. Vaccination should typically be delayed until at least 24 hours after the last dose of Cefoxitin.

• Aminoglycosides (e.g., Gentamicin, Amikacin): Concurrent use of cephalosporins and aminoglycosides may increase the risk of nephrotoxicity (kidney damage). If used together, kidney function must be monitored daily.
• Probenecid: Probenecid inhibits the renal tubular secretion of Cefoxitin. This leads to higher and more prolonged blood levels of the antibiotic. While sometimes used intentionally to increase efficacy, it can also increase the risk of side effects.

• Oral Anticoagulants (e.g., Warfarin): Cephalosporins can potentially enhance the anticoagulant effect of Warfarin by interfering with Vitamin K production in the gut. This increases the risk of bleeding. Your doctor may need to monitor your INR (International Normalized Ratio) more frequently.
• Oral Contraceptives: Some studies suggest that broad-spectrum antibiotics might slightly decrease the effectiveness of hormonal birth control pills by altering gut flora. While the risk is considered low, using a backup method of contraception (like condoms) during treatment is often recommended.

Since Cefoxitin is administered by injection, food does not affect its absorption. There are no specific restrictions regarding dairy, grapefruit, or high-fat meals. However, staying well-hydrated is important to help the kidneys flush the medication from your system.

• Vitamin K Supplements: High doses of Vitamin K may theoretically counteract the mild blood-thinning effect some patients experience on Cefoxitin, though this is rarely clinically significant.
• Probiotics: While probiotics can help prevent antibiotic-associated diarrhea, they should be taken a few hours apart from the antibiotic dose to ensure the Cefoxitin doesn't kill the beneficial bacteria in the supplement.

Cefoxitin is notorious for interfering with several common laboratory tests:

• Urinary Glucose: It may cause a false-positive result for glucose in the urine when using copper reduction tests (e.g., Benedict's solution or Clinitest). It does not affect enzyme-based tests like Clinistix.
• Serum Creatinine: High concentrations of Cefoxitin can interfere with the Jaffe reaction, leading to falsely elevated creatinine levels. Blood samples for creatinine should not be drawn within 2 hours of a Cefoxitin dose.
• Coombs Test: A positive direct Coombs test (which looks for antibodies on red blood cells) can occur in patients receiving cephalosporins, which may interfere with blood cross-matching.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as well as any upcoming lab tests.

Cefoxitin is strictly contraindicated in the following circumstances:

• Known Hypersensitivity to Cefoxitin: Any patient who has had a previous documented allergic reaction to Cefoxitin Sodium must not receive the drug again.
• Severe Cephalosporin Allergy: Patients with a history of immediate and severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, or SJS) to any drug in the cephalosporin class should not be given Cefoxitin. The structural similarities between these drugs mean a repeat reaction is highly likely and potentially fatal.

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• Penicillin Sensitivity: Because of the 10% cross-reactivity rate, Cefoxitin should be used with extreme caution in patients with a history of penicillin allergy. If the previous reaction was mild (e.g., a small rash), the drug may be used with monitoring. If the reaction was severe, it is generally avoided.
• History of Gastrointestinal Disease: Patients with a history of colitis or Crohn's disease should be monitored closely, as they may be more susceptible to severe C. diff infections.
• Severe Renal Impairment: While not a contraindication, the risk of neurotoxicity and drug accumulation is high, requiring significant dose reductions.

Cefoxitin exhibits cross-sensitivity with other beta-lactam antibiotics. This includes:

• Penicillins (e.g., Amoxicillin, Penicillin G)
• Carbapenems (e.g., Meropenem, Imipenem)
• Monobactams (e.g., Aztreonam - though cross-reactivity here is much lower)

If you have an allergy to any of these, your immune system may recognize Cefoxitin as a threat, triggering an allergic response ranging from a mild rash to life-threatening respiratory distress.

> Important: Your healthcare provider will evaluate your complete medical history, including all past drug reactions, before prescribing Cefoxitin.

Cefoxitin is classified by the FDA as Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Cefoxitin crosses the placenta and can be detected in fetal tissues. It is generally considered safe for use during pregnancy when clearly needed, such as for treating serious pelvic or abdominal infections. However, it should only be used if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity (birth defects) associated with Cefoxitin.

Cefoxitin is excreted in human milk in low concentrations. While the amount of drug an infant would ingest is small, it can potentially lead to changes in the infant's gut flora (causing diarrhea or diaper rash) or lead to allergic sensitization. The American Academy of Pediatrics considers many cephalosporins compatible with breastfeeding. Healthcare providers usually recommend monitoring the nursing infant for these symptoms or, in some cases, temporarily pumping and discarding milk during the treatment course.

Cefoxitin is approved for use in children aged 3 months and older. In neonates (infants under 3 months), the drug's half-life is prolonged due to immature kidney function, and the risk of accumulation is higher. Therefore, dosing intervals are usually longer (every 8 to 12 hours instead of every 6). High doses in infants have been associated with changes in renal function, so monitoring is vital. It is not typically the first-choice antibiotic for pediatric meningitis because it does not cross the blood-brain barrier effectively.

Clinical studies of Cefoxitin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, it is known that Cefoxitin is substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitoring renal function (via creatinine clearance) is highly recommended for all geriatric patients receiving Cefoxitin to prevent toxicity.

In patients with a Creatinine Clearance of less than 50 mL/min, the standard dosing regimen will lead to toxic blood levels. Dose adjustments are mandatory. For example, a patient with severe renal failure (CrCl < 5 mL/min) may only receive a dose once every 48 hours. Failure to adjust the dose can lead to seizures and other central nervous system complications.

Since Cefoxitin is not metabolized by the liver, patients with liver cirrhosis or hepatitis do not typically require dose adjustments. However, these patients may have concurrent renal issues (hepatorenal syndrome), which would then necessitate a dose change.

> Important: Special populations require individualized medical assessment and frequent monitoring by a qualified healthcare professional.

Cefoxitin is a bactericidal agent. Its primary molecular mechanism involves the inhibition of bacterial cell wall synthesis. Specifically, Cefoxitin binds to Penicillin-Binding Proteins (PBPs) located on the inner side of the bacterial cell membrane. These PBPs are enzymes (transpeptidases, carboxypeptidases, and endopeptidases) responsible for the assembly and cross-linking of the peptidoglycan layer. By inhibiting these enzymes, Cefoxitin prevents the formation of the cross-bridges that give the cell wall its strength. This results in an incomplete cell wall, leading to bacterial cell death through osmotic lysis. Cefoxitin is particularly effective because its 7-alpha-methoxy group creates steric hindrance, protecting the beta-lactam ring from being broken by many beta-lactamase enzymes.

The efficacy of Cefoxitin is primarily "time-dependent." This means that the most important factor for killing bacteria is the amount of time that the concentration of the drug in the blood remains above the Minimum Inhibitory Concentration (MIC) for the specific bacteria being treated. Unlike some other antibiotics, increasing the dose far above the MIC does not necessarily kill bacteria faster. Therefore, maintaining a consistent dosing schedule (e.g., every 6 hours) is more important than giving one very large dose.

| Parameter | Value |

|---|---|

| Bioavailability | 0% (Oral), 100% (IV/IM) |

| Protein Binding | 65% to 79% |

| Half-life | 45 to 60 minutes |

| Tmax | 20-30 minutes (IM), Immediate (IV) |

| Metabolism | Minimal (<2% in liver) |

| Excretion | Renal 85-98% (Unchanged) |

• Molecular Formula: C16H16N3NaO7S2
• Molecular Weight: 449.4 g/mol
• Solubility: Highly soluble in water; sparingly soluble in organic solvents.
• Description: Cefoxitin Sodium is a white to off-white hygroscopic powder. It is the sodium salt of a cephamycin derived from cephamycin C.

Cefoxitin is a second-generation cephalosporin, specifically categorized as a cephamycin. Other drugs in the second-generation cephalosporin class include Cefuroxime and Cefaclor. However, Cefoxitin is more closely related to Cefotetan in terms of its anaerobic coverage. It is distinct from first-generation cephalosporins (like Cefazolin) due to its increased Gram-negative and anaerobic activity, and distinct from third-generation agents (like Ceftriaxone) which generally have even broader Gram-negative coverage but less potent anaerobic activity.